Dear Editor, Selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) aim to eliminate potential pathogenic microorganisms, such as Gram-negative bacteria and yeasts, from the oropharynx and digestive tract of intensive care unit (ICU) patients [1] [2] [3] . Amphotericin B is mostly used as the antifungal component in SOD and SDD, but is increasingly difficult to acquire due to scarcity of raw materials and is also becoming increasingly expensive. Nystatin is a potential substitute as it is also effective against a broad range of fungi and not absorbed from the digestive tract [4] . However, the effects of both agents on Candida colonization and eradication in SDD have never been compared.
We performed a before-after study evaluating two subsequent changes in SDD in a 32-bed medical-surgical ICU in the Netherlands. All patients admitted for 48 h or longer (i.e., eligible to receive SDD until discharge from the ICU) and who did not receive systemic antifungal therapy were included in the analysis. The local ethics committee waived the need for informed consent.
There were three study periods (Table S1 ): period 1 (16 months), SDD treatment included (q.d.s.) application of a mouth paste containing 2 % polymyxin E, 2 % tobramycin and 2 % amphotericin B, administration (q.d.s) of a suspension with the same components (100 mg polymyxin E, 80 mg tobramycin and 500 mg amphotericin B) through the nasogastric tube, and the systemic administration (q.d.s.) of cefotaxime during the first 4 days of ICU admission (Am/Am); period 2 (17 months), nystatin (2 9 10^6 units per dose) replaced amphotericin B in the enteral solution only (Am/Nys); period 3 (10 months), nystatin replaced amphotericin B in both the oropharyngeal paste and enteral solution (Nys/Nys).
From 1468 patients at least two rectum surveillance cultures were available, 1095 (75 %) were not colonized at the start of ICU admission and Candida acquisition in the rectum was analyzed. Patients' characteristics are on Table S2 . Compared to the reference period (i.e., Am/Am) and after adjustment for baseline imbalances in a Cox regression analysis, (Table S1 ).
In SDD, nystatin was more effective than amphotericin B in eradicating Candida from the rectum and preventing rectal Candida colonization, and is not inferior to amphotericin B in preventing Candida respiratory tract colonization. Nystatin use will improve the costeffectiveness of SDD and SOD. 
